The global smart insulin pens market accounted for USD 0.769 billion in 2023 and is expected to reach at USD 2.30 billion by 2034 with a CAGR of 10.47% during the forecast period 2024-2034. The factors driving the market expansion will involve the increasing prevalence of diabetes, technological advancements, growing adoption of digital health solutions, patient-centered care, and partnerships and collaborations.
Globally, diabetes mellitus has become a significant public health concern. Diabetes, particularly types 1 and 2, is becoming more common, which has increased demand for cutting-edge and effective insulin administration systems like smart insulin pens. Advanced technology like Bluetooth connectivity, smartphone applications, and electronic dose-tracking features are all integrated into smart insulin pens. For instance, Novo Nordisk A/S and Dexcom announced a collaboration in August 2023 to create a smart insulin pen of the future that is coupled with CGM technology to enable automated insulin delivery.
By connectivity type, the Bluetooth segment accounted for the highest revenue-grossing segment in the global smart insulin pens market is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of digital health solutions, advancements in Bluetooth technology, and rising demand for remote monitoring capabilities, driving greater convenience and improved management of diabetes. For instance, Sanofi's next-generation smart insulin pen with Bluetooth connectivity and improved dosing features received CE mark approval in July 2023.
By application, the type 1 diabetes segment accounted for the highest revenue-grossing segment in the global smart insulin pens market in 2023 owing to the growing prevalence of type 1 diabetes, increased focus on personalized diabetes management, and rising adoption of advanced insulin delivery technologies tailored to the needs of type 1 diabetes patients. For instance, Companion Medical launched a new subscription service for its InPen smart insulin pen in September 2023, providing customers with options for data analysis and remote support. Additionally, the type 2 diabetes segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising incidence of type 2 diabetes, expanding diabetic population, and increasing awareness about the benefits of smart insulin pens for managing insulin therapy in type 2 diabetes patients.
By distribution channel, the hospital pharmacies & diabetes clinics/centers segment accounted for the highest revenue-grossing segment in the global smart insulin pens market in 2023 owing to the growing adoption of smart insulin pens in clinical settings, increased focus on optimizing diabetes management protocols, and the convenience of obtaining prescriptions and guidance on insulin therapy in hospital pharmacies and specialized diabetes clinics/centers. For instance, Eli Lilly and Company and Abbott announced a partnership in October 2023 to investigate the possible integration of Lilly's insulin with Abbott's FreeStyle Libre CGM system for use in smart pens. Additionally, the online sales segment is predicted to grow at the fastest CAGR during the forecast period owing to the expansion of e-commerce platforms, increasing consumer preference for online purchasing, and the convenience of accessing a wide range of smart insulin pen options and related products from the comfort of home.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of diabetes, advanced healthcare infrastructure, robust adoption of technological innovations, and supportive regulatory environment fostering the uptake of smart insulin pens in North America. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly increasing diabetic population, improving access to healthcare services, rising awareness about diabetes management, and growing investments in healthcare infrastructure and technology in the Asia Pacific region. For instance, Medtronic plc and a digital health startup partnered in August 2023 to create a cloud-based platform for remote patient management and monitoring through the use of smart insulin pens.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Globally, diabetes mellitus has become a significant public health concern. Diabetes, particularly types 1 and 2, is becoming more common, which has increased demand for cutting-edge and effective insulin administration systems like smart insulin pens. Advanced technology like Bluetooth connectivity, smartphone applications, and electronic dose-tracking features are all integrated into smart insulin pens. For instance, Novo Nordisk A/S and Dexcom announced a collaboration in August 2023 to create a smart insulin pen of the future that is coupled with CGM technology to enable automated insulin delivery.
By connectivity type, the Bluetooth segment accounted for the highest revenue-grossing segment in the global smart insulin pens market is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of digital health solutions, advancements in Bluetooth technology, and rising demand for remote monitoring capabilities, driving greater convenience and improved management of diabetes. For instance, Sanofi's next-generation smart insulin pen with Bluetooth connectivity and improved dosing features received CE mark approval in July 2023.
By application, the type 1 diabetes segment accounted for the highest revenue-grossing segment in the global smart insulin pens market in 2023 owing to the growing prevalence of type 1 diabetes, increased focus on personalized diabetes management, and rising adoption of advanced insulin delivery technologies tailored to the needs of type 1 diabetes patients. For instance, Companion Medical launched a new subscription service for its InPen smart insulin pen in September 2023, providing customers with options for data analysis and remote support. Additionally, the type 2 diabetes segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising incidence of type 2 diabetes, expanding diabetic population, and increasing awareness about the benefits of smart insulin pens for managing insulin therapy in type 2 diabetes patients.
By distribution channel, the hospital pharmacies & diabetes clinics/centers segment accounted for the highest revenue-grossing segment in the global smart insulin pens market in 2023 owing to the growing adoption of smart insulin pens in clinical settings, increased focus on optimizing diabetes management protocols, and the convenience of obtaining prescriptions and guidance on insulin therapy in hospital pharmacies and specialized diabetes clinics/centers. For instance, Eli Lilly and Company and Abbott announced a partnership in October 2023 to investigate the possible integration of Lilly's insulin with Abbott's FreeStyle Libre CGM system for use in smart pens. Additionally, the online sales segment is predicted to grow at the fastest CAGR during the forecast period owing to the expansion of e-commerce platforms, increasing consumer preference for online purchasing, and the convenience of accessing a wide range of smart insulin pen options and related products from the comfort of home.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of diabetes, advanced healthcare infrastructure, robust adoption of technological innovations, and supportive regulatory environment fostering the uptake of smart insulin pens in North America. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly increasing diabetic population, improving access to healthcare services, rising awareness about diabetes management, and growing investments in healthcare infrastructure and technology in the Asia Pacific region. For instance, Medtronic plc and a digital health startup partnered in August 2023 to create a cloud-based platform for remote patient management and monitoring through the use of smart insulin pens.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
Study Coverage
- Market Forecast by Connectivity Type, Appplication, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Smart Insulin Pens Market Report 2023 - 2034
Smart Insulin Pens Market Analysis & Forecast by Connectivity Type 2023 - 2034 (Revenue USD Bn)
- Bluetooth
- USB
Smart Insulin Pens Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Type 1 Diabetes
- Type 2 Diabetes
Smart Insulin Pens Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacies
- Online Sales
- Retail Pharmacies
- Diabetes Clinics/Centers
Smart Insulin Pens Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Smart Insulin Pens Market: Connectivity Type Estimates & Trend Analysis
8. Smart Insulin Pens Market: Application Estimates & Trend Analysis
9. Smart Insulin Pens Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Smart Insulin Pens Market
12. Europe Smart Insulin Pens Market
13. Asia Pacific Smart Insulin Pens Market
14. Latin America Smart Insulin Pens Market
15. MEA Smart Insulin Pens Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Novo Nordisk A/S
- Sanofi
- Companion Medical
- Emperra GmbH
- Eli Lilly and Company
- Bigfoot Biomedical
- Diamesco Co. Ltd.
- Pendiq GmbH
- InPen by Companion Medical
- Jiangsu Delfu Medical Device Co. Ltd.
- Medtronic plc
- Diabnext
- Berlin-Chemie AG
- Diabecare
- Capillary Biomedical Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 0.77 Billion |
| Forecasted Market Value ( USD | $ 2.3 Billion |
| Compound Annual Growth Rate | 10.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
